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Osteoporosis is a complex metabolic bone disorder. Recently it has been appreciated that the “obesity in bone” phenomenon oc-
curs at the expense of bone formation, and that is a key component of the pathology of this disease. Mouse models with altered
bone expression levels of peroxisome proliferator-activated receptor gamma (PPARG) impact bone formation, but genetic studies
connecting PPARG polymorphisms to skeletal phenotypes in humans have proven to be less than satisfactory. One missense poly-
morphism in exon one has been linked to low bone mineral density (BMD), but the most studied polymorphism, Pro12Ala, has
not yet been examined in the context of skeletal phenotype. The studies to date are a promising start in leading to our understand-
ing of the genetic contribution of PPARG to the phenotypes of BMD and fracture risk.
Copyright © 2006 C. Ackert-Bicknell and C. Rosen. This is an open access article distributed under the Creative Commons
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
INTRODUCTION
Osteoporosis currently aﬀects 10 million Americans and an
additional34millionAmericansareconsideredatriskforos-
teoporosis and fracture (http://www.nof.org/ accessed June,
2006). The World Health Organization (WHO) deﬁnes os-
teoporosis as having a BMD with a T-score of less than −2.5
[1], yet in the Rotterdam prospective study of 7806 men and
women over the age of 55, only 44% of women and 21% of
the men with a nonvertebral fracture had a T-score of −2.5
or lower [2] suggesting a need for additional means for pre-
dicting fracture risk. A variety of studies have been done
to examine other risk factors for osteoporosis, both for the
purpose of determining who should undergo further screen-
ing and more importantly, who is at risk for fracture. Os-
teoporosis and the clinically measurable phenotypes such as
BMD and fracture incidence have proven to be very com-
plicated genetic traits with quantitative trait loci (QTLs) for
various bone phenotypes found on almost every chromo-
some in both humans and mice (reviewed in [3, 4]). Yet
BMD is not an independent phenotype, rather it is associ-
ated with many other phenotypes and pathologies such as
diabetes mellitus [5] and coronary artery disease [6]. Body
weight is positively correlated to bone mass and in load-
bearing skeletal sites, increased adiposity is associated with
higher BMD, yet adiposity still inﬂuences BMD at non-load-
bearing sites such as the forearm [7]. PPARG’s role in in-
sulin sensitivity and obesity, as well as work done with mes-
enchymal stem cells have made PPARG an attractive candi-
date gene in studies examining the genetic basis of bone den-
sity.
Meunier et al [8], were the ﬁrst to show that women
with osteoporosis had an increased accumulation of marrow
adipocytes as determined from iliac crest biopsies [8]. More
recent studies have not only conﬁrmed this observation, but
have also shown that volume fraction of the marrow cavity
occupied by adipocytes increased with age in both men and
women and that this is coincident with a decrease in trabec-
ular bone volume. This increase in adipocyte volume is ex-
a c e rb a t e di no s t e o p o r o t i cp a t i e n t s[ 9, 10]. More importantly,
the increased adipocyte volume seen in osteoporotic patients
is negatively correlated with bone formation rate (BFR) [10].
Osteoblasts, the cells responsible for the formation of
bone,arederivedfrommarrowmesenchymalstemcells.This
multipotential stem cell is also able to give rise to chondro-
cytes, muscle cells, marrow stromal cells, and adipocytes
[11]. Lineage allocation is determined by the activation
of lineage-speciﬁc transcription factors such as RUNX2
(CBFA1), an osteoblast-speciﬁc transcription factor or
PPARG, a nuclear receptor shown to be key for the matura-
tion of adipocytes [12, 13]. In preosteoblast cell lines, it has
been shown that expression of PPARG2 can force a commit-
ment to the adipogenic pathway [14], an occurrence that can
be mimicked by the addition of the pharmacological PPARG
ligand BRL4965 [15]. In studies of aging mice, it has been
shown that the increase in adipocyte volume in the bone2 PPAR Research
marrow seen with aging is coincident with an increase in ex-
pression of PPARG2 [16].
PPARG GENE STRUCTURE, FUNCTION,
AND GENETIC LOCATION
PPARG is one of three PPAR nuclear receptors and while
widely expressed, it is primarily found in white adipose
tissue. Like all nuclear receptors, PPARG is composed of
three domains: the N-terminal domain A/B domain, a two-
zinc ﬁnger containing DNA-binding domain, and a C-
terminal ligand-binding domain (17–19). PPARG forms a
heterodimerwiththeretinoicXreceptor-alphaandthiscom-
plex binds to the PPRE (PPAR response element), a direct
repeat of the sequence AGGTCA separated by a single nu-
cleotide spacer, in the target gene [17]. Several classes of
compounds, both endogenous and exogenous, have been
found to act, at least in part, as ligands for PPARG and in-
cluded polyunsaturated fatty acids such as arachidonic acid,
prostaglandins-like compounds, oxidized lipids such as 9-
HODE, and the widely used pharmacological thiazolidine-
dione (TZD) compounds (20).
PPARG is located in humans on 3p25.3a tM bp o s i -
tion 12.3t o1 2 .45 and in mouse on chromosome 6 at 115.8
to 115.93Mb (http://www.ensembl.org v.37, release date:
February, 2006). The gene is composed of nine exons, four
promoters and yields four transcripts via alternate promoter
use and splicing [18–20]. All transcripts contain the exons
numbered one through six. It is the alternate promoters and
leaderexonsthatyieldthefourdistincttranscripts.Asshown
in Figure 1, PPARG1 is transcribed from the g1 promoter
and consists of exons A1, A2 and the ubiquitous exons one
through six [18, 19] and is considered to be universally ex-
pressed [20]. PPARG2, which is only found in adipose tis-
sue [21], is transcribed from the third promoter, which is re-
ferred to as g2, and consists of exon B and exons one through
six [18, 19]. PPARG3, also ubiquitously expressed [20], is
transcribed from the second promoter g3 and consists of ex-
ons A2 and one through six [19]. The last isoform charac-
terized in humans PPARG4 does not contain any of the three
leaderexons,andratherisexpresseddirectlyfromtheg4pro-
moter found immediately in front of exon one [20]. Little
is known about the g4 transcript, although a recently char-
acterized mutation in humans suggests a key role for this
transcript in adipocyte biology [22]. All of the transcripts of
PPARG, with the exception of the transcript generated from
the g2 promoter, yield the same protein product. The pro-
tein product yielded by the g2promoter’s transcript PPARG2
contains 30 extra amino acids on the N-terminus. These ex-
tra30aminoacidshavebeenshowntoincreasethetranscrip-
tional activity of PPARG2 by 5–10-fold over that of PPARG1
(26).
GENETIC MAPPING STUDIES IN HUMANS
Of all of the many genome wide scans published to date,
only Deng et al [23] report a QTL for BMD in the vicinity of
the PPARG gene. They showed a forearm-speciﬁc BMD QTL
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Figure 1: A schematic representation of the PPARG gene. (a) The
PPARG gene is composed of nine exons, named A1, A2, B, 1, 2,
3 ,4 ,5 ,a n d6 ,r e s p e c t i v e l y ,a n df o u rp r o m o t e r s .( b )T h e r ea r ef o u r
major PPARG transcripts, all of which contain exons 1 through 6.
Expression of each transcript is controlled by one of the four pro-
moters. All of the transcripts yield the same protein, except for the
γ2 transcript, which codes for 30 additional amino acids on the N-
terminus.
with a peak at D3S1297 (3p26) with a modest LOD score of
1.82 [23]. A recent meta analysis was done by Lee et al using
data from 11 separate genome-wide scan studies comprised
of 3097 families with 12 685 individuals of a variety of ethnic
backgrounds [24]. These investigators found suggestive evi-
dence for a QTL for BMD in human on 3p25.3t o3 p 2 2 .2, the
exact region of the PPARG gene. The study by Deng et al was
notoneofthestudiesusedinthisanalysis[24].Whilestudies
have examined the heritability of fracture risk [4], no study
to date has mapped a QTL for fracture risk to 3p25.
Several mutations have been discovered in PPARG in hu-
man and have been investigated for their role in obesity, dia-
betes,andmetabolicsyndromeandassucharereviewedelse-
where [25]. Four studies published to date have investigated
the genetic association of PPARG polymorphisms and bone
in humans, as summarized in Figure 2 and Table 1.
A silent His477His (C → T, rs3856806) mutation has
been identiﬁed in humans in the 161st base pair (bp) of
the sixth exon of PPARG and is referred to in the litera-
ture as C161T (as numbered from the beginning of exon 6)
or C1431T (as numbered from the ATG start site). While
this single nucleotide polymorphism (SNP) may actually be
in linkage disequilibrium (LD) with another more causative
mutation, the T allele has been associated with increased
plasma leptin and adipose tissue mass [30]a sw e l la si m -
proved lipid proﬁles in type II diabetes [31, 32]. Two stud-
ies have examined this polymorphism in the context of bone.C. Ackert-Bicknell and C. Rosen 3
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Figure 2: Physical location of the studied human PPARG polymorphisms. Several of these SNPs have been shown to be in high LD. All SNPs
within an LD block are shown as the same color.
Table 1:AsummaryoftheSNPallelesandassociatedbonephenotypesasstudiedtodateinhumans.Theallelesaregiveninparenthesisafter
the SNP number with the major allele in the study population listed ﬁrst. For SNP rs2960422 (∗) no allele frequency in this population was
reported by the authors. SNPs rs11512999, rs709150, and rs1175544 (∗∗) showed no association with either BMD or BUA when analyzed
separately, but an association with BMD was found for the haplotype of rs11512999 (A), rs709150 (C), and rs1175544 (C) in women.
SNP Allele Study population Phenotype Reference
His477His C/T or T/T Postmenopausal Increased total
[26]
(rs3856806, C > T) Japanese women body BMD
His477His any Pre-and Postmenopausal No association
[27] (rs3856806, C > T) Korean women with BMD
rs2960422∗ A/G Men and women in Increased risk for low
[28] mainland China BMD in premenopausal women only
rs1805192 (C > G) C/C Caucasian men and women Site-speciﬁc higher BMD in
[29] females and lower in males
rs4684848 (G > A) any Caucasian men and women No association with BMD [29]
rs1151999 (A > C), A, C, and C
alleles inherited
as a block only
Caucasian men
and women
Site-speciﬁc
lower BMD in
women
[29] rs709150 (C > G) and
rs1175544 (C > T) ∗∗
rs1152004 (T > C) any Caucasian men and women No association with BMD [29]
rs1175381 (T > C) T/C or C/C Caucasian men and women Site-speciﬁc lower BMD in women [29]
rs1186464 (A > G) any Caucasian men and women No association with BMD [29]
In the ﬁrst study of 394 postmenopausal Japanese women,
an association between carriers of at least one T allele and
increased total body BMD was observed [26]. A more re-
cent study of 138 premenopausal and 125 postmenopausal
Koreanwomenshowed no association withthis SNP andany
marker of bone formation, bone resorption, or BMD at the
spine or hip, with the exception of serum osteoprotegerin
(OPG) [27]. In this study, the authors showed a relationship
between low OPG levels and the T allele [27]. While these
two studies contradict one another, it must be remembered
that ﬁrst, the cohort size in these studies were very small and
second, this is a silent polymorphism and is likely in LD with
a more causative mutation. Studies with larger sample sizes
and studies involving diﬀerent ethnic groups must be done
in order to get a more comprehensive picture regarding any
association of this SNP with bone biology.
Two studies have looked at associations between SNPs in
the PPARG gene and bone in larger human cohorts. A study
of 6743 Chinese men and women examined a single SNP
upstream of the ﬁrst promoter of PPARG (rs2960422) and
showed a modest increase in the risk of low BMD with the
heterozygous state of this allele, but only in premenopausal
women. No association was found in either men or post-
menopausal women [28]. It must be noted that to date, this
SNP has only been examined in this one ethnic group.
AmorecomprehensivestudyofSNPsinPPARGandtheir
association with aspects of bone density has been done in
the Framingham Oﬀspring cohort [29]. The population of
study consisted of 740 men and 776 women, with an aver-
ageageof61 yearsold, whowereprimarily Caucasians. Eight
SNPsconstitutingthreeLDblockswereinvestigatedforasso-
ciation with femoral neck, greater trochanter or spine BMD4 PPAR Research
as well as with broadband ultrasound attenuation (BUA) of
the calcaneus. The location of these SNPs and the LD blocks
is summarized in Figure 2. Only one coding SNP was as-
sessed in this study, rs1805192. This SNP, located in the uni-
versal exon one, codes for the substitution of an alanine
(Ala) for the wild-type proline (Pro) but is not to be con-
fused for the much-studied Pro12Ala polymorphism found
in exon B [29]. Homozygosity for the more common Pro
allele wasassociated with increased BMD at both the femoral
neck and lumbar spine as well as increased BUA in women,
when the data was adjusted for age and estrogen status. Con-
versely,menwiththissameallelehadlowerfemoralneckand
trochanter BMD [29]. A full examination of this amino acid
substitution has not been undertaken to date but computer
modeling programs designed to predict the implications of
amino acid change suggest that this substitution could have
structural consequences [33, 34]. The C allele of the SNP
rs1175381 located distal to the polyadenylation signal was
associated with lower BMD at all sites measured in women.
No association with men was reported [29]. Lastly, a haplo-
type block of three SNPs with the associated alleles shown
in brackets, rs1151999 (A), rs709150 (C) and rs1175544
(C), was in women, also associated with lower BMD of the
femoral neck, trochanter, and lumbar spine, but no associa-
tion was found in men. Interestingly all of these allele-BMD
associations were found to be independent of BMI or type II
diabetes (36).
All of the ﬁndings presented in these four studies need
to be conﬁrmed in other cohorts. Both the Chinese cohort
study and the Framingham study are ongoing studies and it
is hoped that future publications from these two groups will
include an examination of such well-studied SNPs such as
thePro12AlaandtheHis477HisSNP.Whilethesestudiesdid
correct for factors such as menopausal status, there may well
be other confounding and/or interacting factors that have
not been taken into account in these studies, thus masking
important results. Previous studies have shown PPARG allele
by environment interactions for a variety of non bone phe-
notypes,warrantingmorecomprehensivestudiesofthisgene
and bone [35–37].
BONE BIOLOGY OF THE Pparg KNOCKOUTANIMAL
Homozygous knock out Ppargtm1Tka mice die at embryonic
day 10.5t o1 1p cd u et op l a c e n t a li n s u ﬃciency and car-
diac defects, making any meaningful examination of skele-
tal biology impossible [38]. In contrast, the Pparg heterozy-
gous knockout mouse (Pparg+/−)i sv i a b l ea n da p p e a r st o
have normal development of all major organs. Akune et al-
have thoroughly examined the bone biology of this haploin-
suﬃcient Pparg mouse [39]. The Pparg+/− male mice show
m a r k e di n c r e a s ei nt r a b e c u l a rb o n ev o l u m ea t8w e e k so f
age as compared to wild-type, and while the volume frac-
tion of trabecular bone (BV/TV) of the distal femur did de-
creasewithageinbothgenotypes,thePparg+/− mousemain-
tained a higher BV/TV than the wild-type controls through
52 weeks of age. Histological analysis showed a more than
50% increase in the number of osteoblasts and a doubling
in the total bone formation rate (BFR) of the haploinsuf-
ﬁcient mice, leading to the conclusion that the function of
individual osteoblasts was not aﬀected. This increase in os-
teoblastnumberwascoincidentwithatrendforadecreasein
adipocyte number. The number of adipocytes in the marrow
increased in the wild-type controls with age, but no change
in adipocyte number was observed in the Pparg+/− mice by
52 weeks of age. The eﬀects of estrogen loss in females on
bone, in the context of low PPARG were also examined. The
loss of one Pparg allele was not protective to bone, as the
Pparg+/− ovariectomized (OVX) mice lost the same propor-
tionofboneafterOVX,asthewild-typeOVXmicelostwhen
compared to the appropriate genotypic sham operated mice
[39].AlthoughRieussetetal,inaseparatestudy,reportslight
total body growth retardation in the Pparg+/− male but not
female mice [40], Akune et alfound no such growth retarda-
tion.
SENESCENCE-ACCELERATED MOUSE P6
The senescence-accelerated series of mice (SAM) were cre-
ated in the 1970s as model for the study of physiological
decline with aging. Two series of mouse lines were created:
the SAMR series served as control lines and the SAMP lines
were selected for signs of advanced aging. The SAMP6 line
was created from the SAMR3 line, from a pedigree that
showed spontaneous leg fractures with advanced age [41].
While indistinguishable from the SAMR1 control strain at
one month of age, bones from the SAMP6 mice showed de-
creasedtrabecularbonevolume,decreasedcorticalthickness,
lower areal BMD, and lower BFR as early as three months
of age. The SAMP6 mice also showed a decreased bend-
ing strength and increased brittleness, and are considered an
excellent model of the senile osteoporosis observed in hu-
mans [42, 43]. The SAMP6 mice show an increase in mar-
row adiposity with aging [44] and a coincident decrease in
osteoblast precursor cells evident as early as three months of
age[42].Morerecently,ithasbeenshownthatPparg2mRNA
levels increase in the marrow with aging in these mice, yet
this could be blocked by a yet-to-be-determined mechanism
upon the administration of 1,25(OH)2D3 (49).
MAPPING STUDIES IN MICE
Two separate mouse mapping crosses in mice have identiﬁed
a QTL for an aspect of bone density or geometry on the dis-
tal 6th chromosome (Chr) in the vicinity of the Pparg gene.
Klein et al have identiﬁed QTL for femoral cross-sectional
area, with a broad peak that includes the genetic location of
Pparg in a C57BL/6J (B6) by DBA/2J cross [45]. Drake et
al have shown a QTL for bone density that colocalized with
adipose tissue mass and bone torsional strength QTLs in the
same genetic location as Klein et al in a cross of the same two
strains, but only after the mice were fed a high fat diet [46].
Our laboratory has conducted intensive studies of a Chr
6 QTL found in a cross of B6 by C3H/HeJ(C3H), Bmd8[ 47].
A congenic mouse was made for the purpose of studying
this QTL in isolation from the large number of other BMDC. Ackert-Bicknell and C. Rosen 5
aﬀecting QTLs found on other chromosomes. The ensuing
strain B6.C3H-6T (6T) was made by introgressing the re-
gion of 6th Chr encompassed by the markers D6Mit93 and
D6Mit150 from C3H onto a B6 background by 9 genera-
tions of selective backcrossing, followed by several genera-
tions of intercrossing. The resulting mouse is homozygous
for B6 alleles for the entire genome except for the region
between D6Mit93 and D6Mit125, which is homozygous for
the C3H alleles [48]. The biology of the 6T mouse has been
well studied. This strain has lower BMD than either the B6
background strain, or the C3H donor strain. 6T mice have
a smaller periosteal circumference, slightly shorter femurs,
and a lower BFR as compared to the B6 background strain
[48].Thereareseveralcandidategenesinthecongenicregion
of the 6T mouse for the various phenotypes seen in the 6T
mouse, including, but not limited to Pparg,a r a c h i d o n a t e5 -
lipoxygenase (Alox5), adiponectin receptor 2 (AdipoR2), and
Wnt5b. While not all of the phenotypes seen in the 6T mouse
can be explained by a single gene alteration, the 6T mouse
does have a strikingly opposite phenotype than that seen in
the Pparg+/− mouse for several key phenotypes. For example,
the 6T mouse has increased numbers of marrow adipocytes
and signiﬁcantly lower trabecular bone volume at all sites
measured when compared to the background strain [48, 49].
Marrow stromal cell cultures show that there are less alkaline
phosphatasestainingcoloniesascomparedtoB6controlcul-
t u r e sa ss o o na s7d a y sa f t e rc u l t u r e ,s u g g e s t i n gad e c r e a s ei n
osteoblastogenesis [49].
Yet the biology of the 6T mouse is not clear cut. In-
creased fat feeding (increase in % kcal from fat), which pro-
vides more exogenous ligand for Pparg, does not increase
total body fat in the female 6T mouse, as it does in the
B6 control strain, nor does it aﬀect the number of marrow
adipocytes. However, decreased fat feeding does improve the
B V / T Vi n6 Tt ol e v e l ss e e ni nc o n t r o lf e dB 6m i c e[ 50]. Dif-
ferences in Pparg transcript levels have been found in both
the liver and in the bone when comparing 6T back to the
background B6 strain [49]. In addition, several polymor-
phisms in both coding and noncoding regions of Pparg have
been found when comparing B6 to C3H. While no nonsyn-
onymousSNPshavebeenfound,severalintriguingpromoter
polymorphisms have been found as well as 12 SNPs in the 3 
UTR (Ackert-Bicknell, unpublished data). Both the biology
of the 6T mouse as well as the number of polymorphisms in
Pparg suggest a key role for this gene in the bone phenotype
of the 6T mouse.
Our original F2 genetic mapping-cross suggested that
this Chr 6 QTL interacted with a locus on the 11th Chr
(56). The Alox15 gene, which codes for an enzyme key
in the formation of 15S-HETE, an endogenous ligand for
PPARG (57), is located on Chr 11 at 70069811–70077674Mb
(http://www.ensembl.org v.37, release date: February, 2006)
and knockout mice for this gene show higher femoral BMD
and femoral stiﬀness [51]. Associations with BMD have been
found in human with SNPs in ALOX12, the gene that codes
for the human functional homologue to the mouse Alox15
[52]. Another member of the ALOX gene family, Alox5,i s
located approximately 1Mb distal to Pparg on mouse Chr
6 and also likely produces a ligand for PPARG. While ex-
pression of Alox15 is much more widespread, the expres-
sion of Alox5 appears to be more limited with the great-
est expression levels seen in bone and white blood cells
(http://symatlas.gnf.org/SymAtlas/).
It is interesting to speculate about the causative gene or
genes in the 6T mouse. In some ways, the phenotypes of
the 6T mice mimic phenotypes of the Pparg+/− mouse, such
as the resistance fat feeding induced obesity [50, 53], yet in
other respects, the 6T mouse is the exact opposite of the
Pparg+/− mouse. Are alterations in the Pparg gene the cause
of this, or is PPARG the mediator of this action under the
control of another gene, such as a member of the Alox gene
family?Cellulardiﬀerentiationinbonecelllineages,asdriven
by PPARG, has been shown to be dependant on the type of
PPARGligandpresent[54],furthersuggestingthealterations
in ligand processing and/or the ability of PPARG to respond
appropriately, may contribute to the interesting physiology
of the 6T mouse. Additional experiments are in progress to
elucidate the genetic mechanisms responsible for the pheno-
types seen in the 6T mouse.
PPARG, DIABETES, AND OBESITY
The Pro12Ala polymorphism has been found in a vari-
ety of ethnic populations [25] and has been shown to de-
crease both the binding of PPARG/RXR heterodimers to
the PPRE and their ability to activate gene transcription
[55]. This polymorphism has not been studied with regard
to an association with bone density, but it has been ex-
amined in the context of several other physiological and
pathological states that are known to impact bone health.
While a clear association between this polymorphism and
BMI or obesity is lacking, a vast number of studies per-
formed to date have linked the Ala allele with decreased
risk for type II diabetes (reviewed in [25, 56]). The few pa-
tients described with dominant negative PPARG mutations
present with early onset and severe insulin resistance [57]
and a few studies have suggested that the His477His muta-
tion may actually be a better predictor of type II diabetes
in certain ethnic populations than the Pro12Ala mutations
[32, 58, 59]. Increased fracture rates are seen in patients
with type II diabetes despite an overall increase in BMD
[5, 60].
In contrast, patients with type I diabetics often have os-
teopenia even after long periods of good metabolic control.
These patients frequently have a decrease in markers of bone
formation, such as serum alkaline phosphatase and osteocal-
cin, as this is thought to be indicative of insuﬃcient bone
accrual beginning at a very young age [60]. These observa-
tions of low bone formation are conﬁrmed in an inducible
mouse model of type I diabetes. Type I diabetic male mice
have been shown to have lower BFR, and the maturation of
osteoblasts from these mice is inhibited [61]. PPARG expres-
sion is shown to be increased in concert with an increase in
marrow adiposity in these same mice, as well as other mark-
ers of adipocyte maturation, suggesting a mechanism for the
l o wb o n em a s ss e e ni nt y p eId i a b e t e s[ 61].6 PPAR Research
Leptin (gene symbol Lep), a hormone secreted by adi-
pose tissue, is thought to inhibit bone formation, as evi-
denced by the fact that both the ob/ob (leptin-deﬁcient) and
db/db (leptin-receptor-deﬁcient) mice have increased bone
mass and increased bone formation rate [62]. It is thought
that leptin mediates its actions on bone via the sympathetic
nervous system [63]. It has been proposed that PPARG sup-
presses Lep gene expression, as expression of Lep is increased
in the Pparg+/− mice [64], providing yet another mechanism
by which PPARG may inﬂuence the biology of bone. In hu-
mans, the His477His polymorphism has been shown to be
associated with plasma leptin levels in obese subjects, yet it
may be argued that this is more a reﬂection of the eﬀects of
PPARG on adipose tissue mass [30].
SUMMARY
PPARG is indisputably important for bone acquisition as
is clearly demonstrated by the phenotype of the Pparg+/−
mouse. While a promising start has been made with regard
to the usefulness of genetic typing for PPARG as predictor of
BMD and fracture risk, too few studies have been completed
for any conclusive statements to be made. The associations
between PPARG and three major inﬂuences on BMD, leptin,
obesity, and diabetes, are encouraging. Genetic mouse mod-
els of low BMD, such as SAMP6 and 6T, are invaluable tools
for the further study of PPARG in bone.
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